WSAUA 2025 Prostate Cancer

Viewing 1-13 of 13 articles

WSAUA 2025: Comparative Performance of UNFOLD AI, PSMA-PET, and mpMRI for Prostate Cancer Localization and Pathologic Staging

WSAUA 2025: Head-to-Head Comparison of Multimodal Imaging in the Detection of Prostate Cancer Using Whole Mount Histopathology as a Reference

WSAUA 2025: Impact of Bone Protecting Agents on Outcomes with Enzalutamide, with or without Radium-223, in Asymptomatic/mildly Symptomatic Patients with Bone mCRPC from PEACE-3

WSAUA 2025: Genomic Classifier Scores and Risk of Histologic Upgrading on Confirmatory Biopsy During Active Surveillance

WSAUA 2025: Efficacy and Safety of Darolutamide + ADT in Black Patients with Metastatic Hormone-Sensitive Prostate Cancer from the Phase 3 ARANOTE Trial

WSAUA 2025: Integrating Genomic Prognostic and Hallmark Signatures from Decipher GRID to Predict Adverse Outcomes in Men on Active Surveillance for Prostate Cancer

WSAUA 2025: PSA Response with Darolutamide + ADT in Patients with Metastatic Hormone-Sensitive Prostate Cancer in ARANOTE

WSAUA 2025: Comprehensive Analysis of the Correlation Between Molecular Subtype and Multimodal Imaging Features of Prostate Cancer

WSAUA 2025: Impact of PSA Doubling Time and Absolute PSA on PSMA PET Positivity in Post-Prostatectomy Biochemical Recurrence

WSAUA 2025: Ultra-Low PSA Response in ARANOTE Correlates with Improved Clinical Outcomes

WSAUA 2025: Impact of Post-Traumatic Stress Disorder on Prostate Cancer Outcomes Following Radical Prostatectomy in a Veteran Population

WSAUA 2025: Darolutamide + ADT Therapy in Patients with Metastatic Hormone-Sensitive Prostate Cancer: Efficacy and Safety by Disease Volume in the Phase 3 ARANOTE Study

WSAUA 2025: Adoption and Outcomes of Tissue Based Genomic Testing for Prostate Cancer in an Integrated Health System